The 3 most recent market catalysts affecting $RXRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 20, 2026
Corporate Catalyst
Bearish
Impact 65
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
The filing details two key events impacting the biotech sector. First, Recursion Pharmaceuticals (RXRX) is facing downward pressure due to a planned sale of 100,000 Class A shares …
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
Recursion Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.
The headline directly points to a corporate catalyst: Recursion Pharmaceuticals (RXRX) reporting worse-than-expected Q2 financial results. This is a significant negative event for …
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 92
Recursion Pharmaceuticals Q2 EPS $(0.25) Misses $(0.22) Estimate, Sales $7.670M Miss $11.947M Estimate
Recursion Pharmaceuticals (RXRX) announced Q2 earnings that fell short of analyst expectations on both the top and bottom lines. The reported loss of $(0.25) per share missed estim…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.